XZP-6924 / Sihuan Pharmaceutical - LARVOL DELTA

XZP-6924: A potent and highly selective USP1 inhibitor with the potential to improve efficacy and overcome resistance to PARP inhibitors (AACR 2024) - "In vitro data reveal that XZP-6924, when combined with Olaparib (PARPi), displays significantly enhanced activities in multiple Olaparib-resistant HRD tumor cells. Current data strongly support further development of XZP-6924. The IND submission is expected in the second half of 2024."

Clinical • Late-breaking abstract • Oncology • BRCA1 • BRCA2 • PCNA • USP1